VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 16, 2007) - Tekmira Pharmaceuticals Corporation (“Tekmira”) (TSX:TKM) today provided an update on the ongoing legal dispute with Protiva Biotherapeutics Inc. (“Protiva”) in response to an announcement made by Protiva. On October 16, 2007, Protiva announced an agreement with Merck & Co., Inc. (“Merck"; NYSE:MRK) whereby Protiva licensed to Merck rights to technology in the field of RNA interference (“RNAi”) on a non-exclusive basis.
